We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.88 | -0.68% | 127.92 | 129.76 | 127.985 | 129.76 | 7,446,078 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Merck & Co. on Friday said the European Commission approved the expanded use of its blockbuster cancer drug Keytruda for certain patients with melanoma, the most serious form of skin cancer.
The Kenilworth, N.J., drugmaker said Keytruda is now approved as monotherapy for the treatment of people ages 12 and older with stage IIB or IIC melanoma and who have undergone complete resection.
Merck said the commission also approved expanding the indications for Keytruda in advanced melanoma and stage III melanoma, as adjuvant treatment following complete resection, to include adolescent patients ages 12 and up.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world. Sales of the drug topped $17 billion last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 07:14 ET (11:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
